Pharmaceutical

Texas Biomedical Research Institute is planning to construct the $10 million Nonhuman Primate Animal Facility in San Antonio. The 45,000-sf building will provide the Southwest National Primate Research Center with additional laboratories and animal housing environments, enabling TBRI to double its population of rhesus macaques. The United States currently faces a shortage of nonhuman primates for biomedical research, with the COVID-19 pandemic highlighting the need for animal models to test the safety and efficacy of new therapies, vaccines, and diagnostics.

The life sciences sector is experiencing an era of unprecedented growth driven by a surge in both public and private funding combined with a post-pandemic sense of urgency and market opportunity. According to a report released by Newmark in January 2021, more than 36 million sf of new construction is expected to be delivered in the nation’s top 14 life science markets, as life science investments more than triple. While demand for life science and biotech facilities has been growing steadily over the past decade, the COVID-19 crisis heightened national awareness around the need for increased research, diagnostic, and domestic manufacturing capabilities. Investors are also seeing significant potential in the future of personalized medicine, genomics, and other life science-related fields, as emerging technologies and research disciplines converge.

Boylston Properties and J.P. Morgan Asset Management began construction in January of 2021 on a 165,600-sf life sciences facility in Watertown, Mass. Located in the Arsenal Yards district, 100 Forge will be the first purpose-built laboratory building in the city. The joint venture development team has secured a $100.1 million construction loan for the project.

Civica Rx began construction in early 2021 on a $124.5 million pharmaceutical manufacturing center in Petersburg, Va. Created in collaboration with Phlow Corp., the 120,000-sf plant will produce sterile injectables for the treatment of COVID-19, emergency room and intensive-care unit treatments, surgeries, and other serious conditions. The facility will feature steam sterilization capabilities, disposable technologies, and advanced automation systems for visual inspection and packaging.

BioMed Realty is planning to create a life sciences innovation campus in Somerville, Mass. The project includes the renovation of an existing 162,000-sf office building and the construction of new facilities on an adjacent 7.5-acre parcel. Offering leasable environments for biomedical, pharmaceutical, and technology companies, the Assembly Square complex will provide 1.3 million sf of research, corporate, and retail space. The mixed-use development will feature multiple roof terraces and a one-acre public park. BioMed Realty acquired the property in early 2021.

Canadian developer Oxford Properties has expanded its real estate portfolio in the United States with the acquisition of four new assets. Representing an investment of $276 million in the burgeoning life sciences industry, the purchase included a total of 415,000 sf of existing space and associated developable land. Oxford Properties plans to spend an additional $500 million to repurpose, renovate, and expand the four structures to create leading-edge lab and office environments for biomedical tenants. 

Silverstein Properties & Cantor Fitzgerald are partnering with University Place Associates to create a biomedical innovation center in Philadelphia. Providing leading-edge lab and office facilities, 3.0 University Place is pre-certified as LEED Platinum v4 BD+C for core and shell, and will also target WELL Core v2 Platinum certification.

BioMed Realty is creating a 482,000-sf life sciences hub in Boston's Seaport District. Previously serving as the corporate headquarters of John Hancock, the building was acquired by BioMed Realty in late 2020. Featuring robust mechanical and electrical systems, the existing structure has attained LEED Platinum sustainable design certification and includes a variety of collaborative meeting areas. The facility will be renovated to provide sophisticated lab and office environments for biomedical companies. Occupancy is expected in the second half of 2022. 

Thermo Fisher Scientific is expanding its global production capacity for vaccines, medicines, and biologic therapies. Construction will begin in mid-2021 on a 130,000-sf facility in Greenville, N.C. Slated for completion in 2022, the standalone structure will accommodate two live-virus filling lines. The project is part of a $500 million investment in the site that will add six new lines in existing buildings to support commercial-scale liquid vial filling and the creation of lyophilized materials. 

Millennium Partners and Beacon Capital Partners will begin construction in late 2021 on a 380,000-sf life sciences facility in Boston. Designed by Handel Architects in collaboration with STUDIO ENÉE, the mixed-use development will provide leading-edge laboratories, offices, and R&D suites clustered around a collaborative open space. Located on 4.6 acres in the Raymond L. Flynn Marine Park, the eight-story project will feature a central core of corrugated metal to celebrate the area's industrial heritage.

Nationwide Children's Hospital is constructing a $100 million gene therapy manufacturing center in Columbus, Ohio. The 185,000-sf facility will enable Andelyn Biosciences, a for-profit subsidiary of Nationwide Children's, to supply pharmaceutical and biotechnology companies with genetic material for use in research and clinical trials. Located in The Ohio State University's Innovation District, the leased structure will feature advanced cGMP environments for commercial-scale manufacturing.

Stanford University dedicated the $210 million Biomedical Innovation Building in November of 2020 in Palo Alto, Calif. Designed by ZGF Architects with Research Facilities Design (RFD) as laboratory design consultant, the 190,439-gsf facility strategically collocates investigators with expertise in cardiovascular medicine, pediatrics, orthopaedics, immunotherapy, personalized genomics, otolaryngology, and asthma and allergy.

The Institute of Cancer Research (ICR) opened the £75 million Centre for Cancer Drug Discovery in London in November of 2020. Located in the borough of Sutton, the 78,580-sf facility features team laboratories where biologists, evolutionary scientists, chemists, pharmacologists, data scientists, and clinicians can discover new solutions for cancer evolution and drug resistance.

The University of Oregon dedicated the first phase of the Phil and Penny Knight Campus for Accelerating Scientific Impact in December of 2020 in Eugene. Designed by Ennead Architects and Bora Architects to encourage interaction and collaboration, the $225 million, 160,000-sf building offers leading-edge biomedical laboratories, core facilities, classrooms, and an innovation center.

ApiJect will break ground in December of 2020 on the Gigafactory campus in Durham, N.C. Strategically sited in Research Triangle Park, the complex will be the world’s largest pharmaceutical fill-finish facility, offering an annual production capacity of three billion single-dose prefilled injectors. Funded by a federal loan of $590 million, the one million-sf project will provide BSL-2 manufacturing areas, cold and ultra-cold storage infrastructure, and an onsite needle and cannula factory.